Particle.news
Download on the App Store
17 ARTICLES
·
8h ago

Eli Lilly’s Oral Obesity Pill Triggers Stock Slide After Modest Weight-Loss Results

Investors punished the stock following modest weight-loss data, with Lilly preparing a year-end FDA submission for a global roll-out.

Image
Set of white round medical pills on blue pastel background, top view
Image
Image

Overview

  • Orforglipron achieved 12.4% average weight loss over 72 weeks in its pivotal ATTAIN-1 Phase 3 trial, compared with 0.9% in the placebo group.
  • The pill’s efficacy trailed established injectables such as Wegovy (15% weight loss) and Zepbound (21%), raising questions about its competitive edge.
  • Lilly’s shares fell more than 10% on August 7 after investors expressed disappointment in the trial’s modest results.
  • Safety outcomes mirrored other GLP-1 therapies, with primarily mild-to-moderate gastrointestinal side effects and about 10% of participants discontinuing due to adverse reactions.
  • Eli Lilly plans to submit orforglipron to the FDA by year-end and is preparing for global launches as regulators and health systems assess its cost, convenience and comparative benefits.